Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nibrozetone (Primary) ; Irinotecan
  • Indications Cholangiocarcinoma; Colon cancer; Gallbladder cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms PAYLOAD
  • Sponsors EpicentRx

    • Most Recent Events

    • 12 May 2022 Status changed from active, no longer recruiting to discontinued.
    • 21 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
    • 31 May 2020 Results (n=12) presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top